Molecular Pharmacology Training Program
分子药理学培训项目
基本信息
- 批准号:10398169
- 负责人:
- 金额:$ 41.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Pharmacology is at a crossroads. Although technological advances in chemistry and biology have transformed
drug discovery, our ability to develop new therapeutics has lagged behind our clinical needs. This gap reflects a
disconnect between basic science discovery and translational research, and addressing this challenge will require
scientists who can bridge these two areas. Toward this goal, the Stanford Molecular Pharmacology Training Program
(MPTP) aims to empower predoctoral students across the biosciences with specialized training in drug discovery and
development.
The MPTP is founded on the rich history of pharmacology research and education at Stanford, and it now
transcends conventional academic boundaries. Our training program draws upon an outstanding group of 26 highly
collaborative Stanford faculty from multiple departments, and it builds upon the strength of SPARK, a translational
research initiative that was created at Stanford in 2006. In addition to their independent research with MPTP faculty,
our trainees receive formal course work in drug discovery, and they attend weekly presentations by SPARK-affiliated
experts in pharma/biotech, patent law, venture capital, clinical medicine, and other areas related to therapeutic
development. MPTP students also participate in summer biotech internships and clinical shadowing opportunities,
supplementing their academic training with industrial and clinical experiences.
These training activities are integrated with courses on the responsible conduct of research, rigor, and
reproducibility, weekly student/faculty research forums, annual retreats, grant writing and science communication
workshops, and outreach opportunities. Our predoctoral students are also encouraged to propose translational
projects, which are reviewed and funded by SPARK on a competitive basis. These team-based projects provide hands-
on, real-world experience in therapeutic development and direct interactions with industry veterans and experts. Our
program carefully tracks student research progress, faculty mentorship, and program effectiveness to enable the
MPTP to continually evolve to meet its educational mission. To train scientific leaders and innovators who will impact
communities throughout the United States, we have also established recruitment and retention strategies to foster
student diversity, leveraging Stanford resources and mobilizing the MPTP community.
Through its innovative curriculum and partnerships with SPARK and industry, the MPTP will impart its students
with rigorous training in basic science and an understanding of drug discovery and development. Graduates of our
training program will be uniquely able to translate fundamental discoveries into clinical advances, and they will be well-
positioned to become scientific leaders in academia, industry, government, and other sectors.
药理学正处于十字路口。尽管化学和生物学的技术进步已经改变了
药物发现,我们开发新疗法的能力已经落后于我们的临床需求。这一差距反映了
基础科学发现和转化研究之间的脱节,解决这一挑战将需要
科学家们可以将这两个领域联系起来。为了实现这一目标,斯坦福大学分子药理学培训计划
(MPTP)旨在为生物科学领域的博士前学生提供药物发现和
发展
MPTP建立在斯坦福大学丰富的药理学研究和教育历史的基础上,现在它
超越了传统的学术界限。我们的培训计划借鉴了一个优秀的26个高度
协作斯坦福大学教师来自多个部门,它建立在SPARK的力量,一个翻译
这是2006年在斯坦福大学创立的一个研究项目。除了他们与MPTP教师的独立研究,
我们的学员接受药物发现的正式课程,他们参加SPARK附属的每周报告会。
制药/生物技术、专利法、风险投资、临床医学和其他与治疗相关领域的专家
发展MPTP学生还参加暑期生物技术实习和临床跟踪机会,
用工业和临床经验补充他们的学术训练。
这些培训活动与关于负责任地进行研究、严谨性和
再现性,每周学生/教师研究论坛,年度务虚会,赠款写作和科学交流
讲习班和外联机会。我们的博士前学生也鼓励提出翻译
这些项目由SPARK在竞争的基础上审查和资助。这些团队项目提供了手-
在治疗开发方面的实际经验以及与行业资深人士和专家的直接互动。我们
该计划仔细跟踪学生的研究进展,教师指导和计划的有效性,使
MPTP不断发展,以满足其教育使命。培养科学领导者和创新者,
在美国各地的社区,我们还建立了招聘和保留战略,以促进
学生的多样性,利用斯坦福大学的资源和动员MPTP社区。
通过其创新的课程和与SPARK和行业的合作伙伴关系,MPTP将传授给学生
在基础科学和药物发现和开发的理解严格的培训。我们的毕业生
培训计划将是唯一能够将基础发现转化为临床进展,他们将很好地-
定位成为学术界,工业界,政府和其他部门的科学领导者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES K CHEN其他文献
JAMES K CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES K CHEN', 18)}}的其他基金
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
- 批准号:
10640894 - 财政年份:2021
- 资助金额:
$ 41.63万 - 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
- 批准号:
10407067 - 财政年份:2021
- 资助金额:
$ 41.63万 - 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
- 批准号:
10299142 - 财政年份:2021
- 资助金额:
$ 41.63万 - 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
- 批准号:
10470960 - 财政年份:2019
- 资助金额:
$ 41.63万 - 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
- 批准号:
10018041 - 财政年份:2019
- 资助金额:
$ 41.63万 - 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
- 批准号:
10673682 - 财政年份:2019
- 资助金额:
$ 41.63万 - 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
- 批准号:
10456372 - 财政年份:2019
- 资助金额:
$ 41.63万 - 项目类别:
Gli1-selective inhibitors of the Hedgehog signaling pathway
Hedgehog 信号通路的 Gli1 选择性抑制剂
- 批准号:
9100825 - 财政年份:2015
- 资助金额:
$ 41.63万 - 项目类别:
相似海外基金
National Career Development Program for Researchers in Pediatric Clinical Pharmacology
儿科临床药理学研究人员国家职业发展计划
- 批准号:
11001312 - 财政年份:2024
- 资助金额:
$ 41.63万 - 项目类别:
Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
- 批准号:
10637938 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Training in Systems Pharmacology and Toxicology (T-SPaT)
系统药理学和毒理学培训 (T-SPaT)
- 批准号:
10714918 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Clinical Pharmacology Quality Assurance (CPQA)
临床药理学质量保证(CPQA)
- 批准号:
10850504 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
基本标题:预防临床前药理学和毒理学任务订单标题:使用人单克隆抗体 ATI-1013 进行尼古丁减少治疗
- 批准号:
10932479 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Pharmacology Consulting Services in relation to Pharmaceutical Development with Pain expertise. 09/12/2023 - 09/11/2024
与具有疼痛专业知识的药物开发相关的药理学咨询服务。
- 批准号:
10949065 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Fellowship Programs
Understanding the clinical pharmacology of marijuana-tobacco co-administration
了解大麻-烟草联合用药的临床药理学
- 批准号:
10660409 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别:
Learning How to Give Casual Explanations for Large Scale Virtual and Morphological Pharmacology
学习如何对大规模虚拟和形态药理学进行随意解释
- 批准号:
10713386 - 财政年份:2023
- 资助金额:
$ 41.63万 - 项目类别: